A Randomized, Double-Blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of Subcutaneously Administered RBD5044 in Healthy Subjects
Latest Information Update: 09 Dec 2024
At a glance
- Drugs RBD 5044 (Primary)
- Indications Hyperlipidaemia
- Focus Adverse reactions
- Sponsors Suzhou Ribo Life Science
Most Recent Events
- 04 Dec 2024 Status changed from recruiting to completed.
- 30 Oct 2023 Status changed from not yet recruiting to recruiting.
- 20 Sep 2022 New trial record